XENEXenon Pharmaceuticals Inc.

$63.80

The financials

Xenon Pharmaceuticals Inc. by the numbers

Xenon Pharmaceuticals Inc. (XENE) reported revenue of $0 in Q1 2026 (quarter ended March 31, 2026), down 100% from the same quarter a year earlier. That came with net loss of $102M. For the full year FY2025, revenue was $7.5M and net income −$346M.

Xenon Pharmaceuticals Inc. income statement, Q1 2026 against the same quarter a year earlier
Income statementQ1 2026Q1 2025Change
Revenue$0$7.5Mto a loss
Operating income−$112M−$73Mn/a
Net income−$102M−$65Mn/a
Diluted EPS−$1.17−$0.83n/a